Chen Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chen Xu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Ning Dong
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine
7 shared publications Yunbing Li
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine
4 shared publicationsLili Huang
Laboratory Department, Children's Hospital of Soochow University, Suzhou, China
3 shared publicationsXiangkun Zeng
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine
3 shared publicationsXiaofan Li
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine
3 shared publicationsYuanyuan Li
Department of Medical Microbiology, Experimental Center, Suzhou Medical College of Soochow University
3 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
Repurposing Penfluridol to combat mycobacteria via bioenergetic collapse
Drug-resistant Mycobacterium tuberculosis (Mtb) infections constitute a persistent and severe public health crisis worldwide. Standard anti-tuberculosis (anti-TB) therapies often fail to eradicate resistant strains, resulting in poor clinical outcomes and underscoring the demand for new treatment options. Drug repurposing offers a practical and time-efficient approach to accelerate the development of new anti-mycobacterial regimens. In this work, we evaluated the antimycobacterial potency of penfluridol (PL), a Food and Drug Administration (FDA)-approved antipsychotic drug, and explored its functional mechanism against mycobacteria. Our experimental data revealed that PL compromises mycobacterial membrane integrity and depletes the proton motive force (PMF), leading to disrupted energy metabolism and mycobacterial growth inhibition. PMF depletion disables energy-reliant efflux systems, facilitates intracellular PL accumulation, and further deteriorates membrane damage, creating a sustained bactericidal effect. Notably, continuous PL exposure rarely induces stable drug resistance. These observations suggest that PL can be repurposed for treating drug-resistant TB and confirm that targeting bacterial bioenergetics is an effective strategy to overcome clinical antimicrobial resistance. IMPORTANCE: Tuberculosis (TB) remains a major threat to global public health, and the widespread emergence of drug-resistant strains has substantially compromised the efficacy of existing anti-TB regimens. The scarcity of approved anti-TB drugs, combined with lengthy treatment regimens and frequent therapeutic failure, further exacerbates the global TB crisis, highlighting an urgent need for safe and effective alternative therapies. Drug repurposing serves as a time-saving and reliable strategy to accelerate anti-TB drug development. This study explores the antimycobacterial efficacy and unique working mechanism of the clinically approved agent penfluridol (PL). Our findings identify a feasible candidate for treating drug-resistant TB and provide a valuable bioenergetic-targeting strategy to combat bacterial antimicrobial resistance.
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
Open AccessRepurposing Penfluridol to combat mycobacteria via bioenergetic collapse
Drug-resistant Mycobacterium tuberculosis (Mtb) infections constitute a persistent and severe public health crisis worldwide. Standard anti-tuberculosis (anti-TB) therapies often fail to eradicate resistant strains, resulting in poor clinical outcomes and underscoring the demand for new treatment options. Drug repurposing offers a practical and time-efficient approach to accelerate the development of new anti-mycobacterial regimens. In this work, we evaluated the antimycobacterial potency of penfluridol (PL), a Food and Drug Administration (FDA)-approved antipsychotic drug, and explored its functional mechanism against mycobacteria. Our experimental data revealed that PL compromises mycobacterial membrane integrity and depletes the proton motive force (PMF), leading to disrupted energy metabolism and mycobacterial growth inhibition. PMF depletion disables energy-reliant efflux systems, facilitates intracellular PL accumulation, and further deteriorates membrane damage, creating a sustained bactericidal effect. Notably, continuous PL exposure rarely induces stable drug resistance. These observations suggest that PL can be repurposed for treating drug-resistant TB and confirm that targeting bacterial bioenergetics is an effective strategy to overcome clinical antimicrobial resistance. IMPORTANCE: Tuberculosis (TB) remains a major threat to global public health, and the widespread emergence of drug-resistant strains has substantially compromised the efficacy of existing anti-TB regimens. The scarcity of approved anti-TB drugs, combined with lengthy treatment regimens and frequent therapeutic failure, further exacerbates the global TB crisis, highlighting an urgent need for safe and effective alternative therapies. Drug repurposing serves as a time-saving and reliable strategy to accelerate anti-TB drug development. This study explores the antimycobacterial efficacy and unique working mechanism of the clinically approved agent penfluridol (PL). Our findings identify a feasible candidate for treating drug-resistant TB and provide a valuable bioenergetic-targeting strategy to combat bacterial antimicrobial resistance.
- Open Access
- 1 September 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (9)
Global Shigella epidemiology and vaccine coverage stratified by socioeconomic development levels, 1934–2025
The prominence of Shigella was underscored by the 2024 WHO Bacterial Priority Pathogens List (BPPL), which elevated fluoroquinolone-resistant Shigella spp. to the high-priority group due to its burden and increasing resistance in low- and middle-income countries (LMICs) (1). In economically transitioning countries, Shigella dominance has shifted between S. flexneri and S. sonnei, emphasizing the need for further investigation of Shigella’s global epidemiology and its correlation with socioeconomic factors (2).
- 1 September 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (9)
Open AccessGlobal Shigella epidemiology and vaccine coverage stratified by socioeconomic development levels, 1934–2025
The prominence of Shigella was underscored by the 2024 WHO Bacterial Priority Pathogens List (BPPL), which elevated fluoroquinolone-resistant Shigella spp. to the high-priority group due to its burden and increasing resistance in low- and middle-income countries (LMICs) (1). In economically transitioning countries, Shigella dominance has shifted between S. flexneri and S. sonnei, emphasizing the need for further investigation of Shigella’s global epidemiology and its correlation with socioeconomic factors (2).
- Open Access
Functional and evolutionary insights into the emerging tet (X4)-carrying non-O1/O139 Vibrio cholerae from retail pork
The tigecycline resistance gene tet (X4) is prevalent in Enterobacteriaceae, particularly in Escherichia coli . To our knowledge, no study has reported the dissemination dynamics of tet (X4) in Vibrio spp. Herein, we isolated and characterized a first tet (X4)-positive non-O1/O139 Vibrio cholerae isolate from retail pork. Genomic sequencing identified a novel tet (X4) variant in the V. cholerae chromosome, harboring a G568A nucleotide substitution that resulted in an Ala190Thr (A190T) amino acid substitution in Tet(X4). While this Tet(X4)-A190T variant conferred lower phenotypic resistance to tetracyclines (including tigecycline) than the wild-type Tet(X4), its overall catalytic efficiency against these antibiotics was paradoxically enhanced despite a reduced substrate affinity. Genomic comparisons revealed that two copies of IS CR2 flanked the variant gene, and the structure was IS CR2 - hp - hp - abh - tet (X4) G568A -IS CR2 , which is highly homologous to the reported E. coli plasmids carrying tet (X4). In addition, it confirmed the presence of an IS CR2 -mediated circular intermediate, proving this module’s capacity for horizontal transfer of the tet (X4) G568A variant. Furthermore, the IS CR2 – tet (X4) genetic structure carrying the G568A substitution was integrated within a chimeric SXT/R391-like integrative and conjugative element (ICE), which is also serving as a vehicle for genetic dissemination. As per our knowledge, this is the first report on the emergence of SXT/R391-like ICE carrying tet (X4) in Vibrio strains. Our finding demonstrates that the clinically relevant tigecycline resistance gene tet (X4), previously confined mainly to Enterobacterales from humans and livestock, is now actively spreading into environmental Vibrio populations. This cross-species transfer highlights a previously underappreciated ecological and public health concern in aquatic ecosystems. Importance: Tigecycline serves as a vital last-resort antibiotic against severe multidrug-resistant bacterial infections, but its clinical efficacy is currently threatened by the rapid global dissemination of resistance genes like tet (X4). While land-based agriculture is a well-recognized reservoir for these genes, the role of aquatic ecosystems and environmental pathogens, such as V. cholerae , in harboring tet (X) determinants remains largely unexplored. In this study, we characterize a non-O1/non-O139 V. cholerae isolate from retail pork that harbors a naturally occurring, chromosomally integrated tet (X4) G568A variant. This novel variant exhibits elevated catalytic efficiency against tetracycline antibiotics. The tet (X4) G568A allele is embedded in a highly conserved structural module (IS CR2 – tet (X4)– abh – hp – hp- IS CR2 ) flanked by two IS CR2 repeats, which is integrated into an SXT/R391-like ICE at the chromosomal prfC locus. These findings provide the first high-confidence genomic evidence of tet (X4) in V. cholerae , highlighting aquatic Vibrio species as critical environmental reservoirs for clinically significant antimicrobial resistance genes and emphasizing the urgent need for continuous genomic surveillance.
Open AccessFunctional and evolutionary insights into the emerging tet (X4)-carrying non-O1/O139 Vibrio cholerae from retail pork
The tigecycline resistance gene tet (X4) is prevalent in Enterobacteriaceae, particularly in Escherichia coli . To our knowledge, no study has reported the dissemination dynamics of tet (X4) in Vibrio spp. Herein, we isolated and characterized a first tet (X4)-positive non-O1/O139 Vibrio cholerae isolate from retail pork. Genomic sequencing identified a novel tet (X4) variant in the V. cholerae chromosome, harboring a G568A nucleotide substitution that resulted in an Ala190Thr (A190T) amino acid substitution in Tet(X4). While this Tet(X4)-A190T variant conferred lower phenotypic resistance to tetracyclines (including tigecycline) than the wild-type Tet(X4), its overall catalytic efficiency against these antibiotics was paradoxically enhanced despite a reduced substrate affinity. Genomic comparisons revealed that two copies of IS CR2 flanked the variant gene, and the structure was IS CR2 - hp - hp - abh - tet (X4) G568A -IS CR2 , which is highly homologous to the reported E. coli plasmids carrying tet (X4). In addition, it confirmed the presence of an IS CR2 -mediated circular intermediate, proving this module’s capacity for horizontal transfer of the tet (X4) G568A variant. Furthermore, the IS CR2 – tet (X4) genetic structure carrying the G568A substitution was integrated within a chimeric SXT/R391-like integrative and conjugative element (ICE), which is also serving as a vehicle for genetic dissemination. As per our knowledge, this is the first report on the emergence of SXT/R391-like ICE carrying tet (X4) in Vibrio strains. Our finding demonstrates that the clinically relevant tigecycline resistance gene tet (X4), previously confined mainly to Enterobacterales from humans and livestock, is now actively spreading into environmental Vibrio populations. This cross-species transfer highlights a previously underappreciated ecological and public health concern in aquatic ecosystems. Importance: Tigecycline serves as a vital last-resort antibiotic against severe multidrug-resistant bacterial infections, but its clinical efficacy is currently threatened by the rapid global dissemination of resistance genes like tet (X4). While land-based agriculture is a well-recognized reservoir for these genes, the role of aquatic ecosystems and environmental pathogens, such as V. cholerae , in harboring tet (X) determinants remains largely unexplored. In this study, we characterize a non-O1/non-O139 V. cholerae isolate from retail pork that harbors a naturally occurring, chromosomally integrated tet (X4) G568A variant. This novel variant exhibits elevated catalytic efficiency against tetracycline antibiotics. The tet (X4) G568A allele is embedded in a highly conserved structural module (IS CR2 – tet (X4)– abh – hp – hp- IS CR2 ) flanked by two IS CR2 repeats, which is integrated into an SXT/R391-like ICE at the chromosomal prfC locus. These findings provide the first high-confidence genomic evidence of tet (X4) in V. cholerae , highlighting aquatic Vibrio species as critical environmental reservoirs for clinically significant antimicrobial resistance genes and emphasizing the urgent need for continuous genomic surveillance.
- 20 July 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
The Effects of High-Intensity Interval Training on Fatigue Severity in Individuals with Chronic Diseases
Objective: This systematic review and meta-analysis aimed to synthesize the effects of high-intensity interval training on fatigue severity in individuals with chronic diseases. Design: A literature search was conducted across seven databases. Randomized controlled trials comparing changes in fatigue severity, measured using validated fatigue scales, between high-intensity interval training and no exercise or moderate-intensity continuous training in individuals with chronic diseases were included. Methodological quality was assessed using the PEDro scale, and certainty of evidence was evaluated using the GRADE framework. Results: Seventeen trials involving 717 participants were included. Compared with no exercise, high-intensity interval training was associated with a small reduction in fatigue severity (standardized mean difference =−0.31, 95% confidence interval −0.61 to −0.01; I²=54%; N=10 studies; n=468 participants; very low certainty of evidence). Compared with moderate-intensity continuous training, the pooled difference in fatigue severity was less than small (standardized mean difference =−0.09, 95% confidence interval −0.37 to 0.19; N=8; n=315). Conclusion: High-intensity interval training may represent a potential exercise strategy for fatigue management in individuals with chronic diseases. Future randomized controlled trials are needed to further evaluate its effects on fatigue severity in these populations.
- 20 July 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
The Effects of High-Intensity Interval Training on Fatigue Severity in Individuals with Chronic Diseases
Objective: This systematic review and meta-analysis aimed to synthesize the effects of high-intensity interval training on fatigue severity in individuals with chronic diseases. Design: A literature search was conducted across seven databases. Randomized controlled trials comparing changes in fatigue severity, measured using validated fatigue scales, between high-intensity interval training and no exercise or moderate-intensity continuous training in individuals with chronic diseases were included. Methodological quality was assessed using the PEDro scale, and certainty of evidence was evaluated using the GRADE framework. Results: Seventeen trials involving 717 participants were included. Compared with no exercise, high-intensity interval training was associated with a small reduction in fatigue severity (standardized mean difference =−0.31, 95% confidence interval −0.61 to −0.01; I²=54%; N=10 studies; n=468 participants; very low certainty of evidence). Compared with moderate-intensity continuous training, the pooled difference in fatigue severity was less than small (standardized mean difference =−0.09, 95% confidence interval −0.37 to 0.19; N=8; n=315). Conclusion: High-intensity interval training may represent a potential exercise strategy for fatigue management in individuals with chronic diseases. Future randomized controlled trials are needed to further evaluate its effects on fatigue severity in these populations.
- Open Access
- 22 August 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (1) , 101221
Carbapenemase-producing Citrobacter species in Chinese children, 2015–24: emerging cefiderocol-resistant hypervirulent clones
- 22 August 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (1) , 101221
Open AccessCarbapenemase-producing Citrobacter species in Chinese children, 2015–24: emerging cefiderocol-resistant hypervirulent clones
- 28 December 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (2) , 447-452
Characterization of an ST38 carbapenem-resistant and highly virulent Escherichia coli carrying conjugatively transferable ColV virulence–resistance and blaNDM-5-positive resistance plasmids
Objectives: To characterize an Escherichia coli strain causing bloodstream infection encoding both high-virulence and carbapenem-resistance phenotypes. Methods: Antimicrobial susceptibility testing, WGS and bioinformatics analysis were performed to characterize strain E1. The function of the ColV plasmid was investigated by the Galleria mellonella infection model, serum killing and macrophage killing assays. The fitness effect of the ColV plasmid was tested by growth curve, plasmid stability tests and the in vitro competition assay. The conjugation assay was performed to test the transferability of the ColV and blaNDM-5-carrying plasmids. Results: E. coli E1 from bloodstream infection was MDR and highly virulent in the G. mellonella infection model. It belonged to phylogroup D, ST38 and serotype O7:H8. E1 carried a conjugatively transferable IncI1-type blaNDM-5-positive plasmid, which conferred carbapenem resistance, a conjugative IncFIB/FII-type ColV plasmid encoding an array of virulence-associated genes and antibiotic resistance genes blaTEM-1B, strAB and sul2, and seven other plasmids. Co-transfer of the ColV plasmid and the blaNDM-5-positive plasmid was observed. The ColV virulence–resistance hybrid plasmid contributed to the virulence, resistance to serum killing, and macrophage phagocytosis in E. coli E1. The carriage of this ColV plasmid did not constitute an in vitro fitness burden to strain E1 but caused fitness costs to E. coli strain EC600. Conclusions: The emergence of such a highly virulent and resistant strain with conjugative blaNDM-5-positive and ColV plasmids posed a significant threat to public health. Implementation of control measures is needed to prevent such strains from further disseminating in hospital settings and the community.
- 28 December 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (2) , 447-452
Characterization of an ST38 carbapenem-resistant and highly virulent Escherichia coli carrying conjugatively transferable ColV virulence–resistance and blaNDM-5-positive resistance plasmids
Objectives: To characterize an Escherichia coli strain causing bloodstream infection encoding both high-virulence and carbapenem-resistance phenotypes. Methods: Antimicrobial susceptibility testing, WGS and bioinformatics analysis were performed to characterize strain E1. The function of the ColV plasmid was investigated by the Galleria mellonella infection model, serum killing and macrophage killing assays. The fitness effect of the ColV plasmid was tested by growth curve, plasmid stability tests and the in vitro competition assay. The conjugation assay was performed to test the transferability of the ColV and blaNDM-5-carrying plasmids. Results: E. coli E1 from bloodstream infection was MDR and highly virulent in the G. mellonella infection model. It belonged to phylogroup D, ST38 and serotype O7:H8. E1 carried a conjugatively transferable IncI1-type blaNDM-5-positive plasmid, which conferred carbapenem resistance, a conjugative IncFIB/FII-type ColV plasmid encoding an array of virulence-associated genes and antibiotic resistance genes blaTEM-1B, strAB and sul2, and seven other plasmids. Co-transfer of the ColV plasmid and the blaNDM-5-positive plasmid was observed. The ColV virulence–resistance hybrid plasmid contributed to the virulence, resistance to serum killing, and macrophage phagocytosis in E. coli E1. The carriage of this ColV plasmid did not constitute an in vitro fitness burden to strain E1 but caused fitness costs to E. coli strain EC600. Conclusions: The emergence of such a highly virulent and resistant strain with conjugative blaNDM-5-positive and ColV plasmids posed a significant threat to public health. Implementation of control measures is needed to prevent such strains from further disseminating in hospital settings and the community.
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0093523
A novel virulence plasmid encoding yersiniabactin, salmochelin, and RmpADC from hypervirulent Klebsiella pneumoniae of distinct genetic backgrounds
Hypervirulent Klebsiella pneumoniae (hvKP) is increasingly reported worldwide as a major clinical and public health threat. The virulence of hvKP is attributed largely to the carriage of virulence plasmids (KpVPs). To date, two dominant types of KpVP have been identified, namely, KpVP-1 and KpVP-2. In this study, we reported two hvKP strains from bloodstream infections that carry highly identical virulence plasmids that exhibited Galleria mellonella infection model, and possess high-level macrophage-killing resistance in vitro . Apart from the intrinsic non-susceptibility to ampicillin, both strains were susceptible to commonly used antibiotics. The virulence plasmid carried virulence genes rmpADC , iroBCDN ( iro1 ), and the ybt locus ( ybt4 ) which was not present on either KpVP-1 or KpVP-2. It did not carry antimicrobial resistance genes but carried an incomplete conjugation machinery containing only the traH and traF genes. The KpVP-3 plasmid was stably maintained in both hvKP strains and could not be eliminated with SDS treatment or by serial passage on stress-free agar plates. KpVP-3 was non-self-transmissible under experimental conditions. Data mining suggested KpVP-3-type plasmids have emerged in different countries including China, Australia, and the USA. The emergence of this novel virulence plasmid might pose a potential threat to public health. Heightened efforts are required to study its dissemination mechanism.
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0093523
A novel virulence plasmid encoding yersiniabactin, salmochelin, and RmpADC from hypervirulent Klebsiella pneumoniae of distinct genetic backgrounds
Hypervirulent Klebsiella pneumoniae (hvKP) is increasingly reported worldwide as a major clinical and public health threat. The virulence of hvKP is attributed largely to the carriage of virulence plasmids (KpVPs). To date, two dominant types of KpVP have been identified, namely, KpVP-1 and KpVP-2. In this study, we reported two hvKP strains from bloodstream infections that carry highly identical virulence plasmids that exhibited Galleria mellonella infection model, and possess high-level macrophage-killing resistance in vitro . Apart from the intrinsic non-susceptibility to ampicillin, both strains were susceptible to commonly used antibiotics. The virulence plasmid carried virulence genes rmpADC , iroBCDN ( iro1 ), and the ybt locus ( ybt4 ) which was not present on either KpVP-1 or KpVP-2. It did not carry antimicrobial resistance genes but carried an incomplete conjugation machinery containing only the traH and traF genes. The KpVP-3 plasmid was stably maintained in both hvKP strains and could not be eliminated with SDS treatment or by serial passage on stress-free agar plates. KpVP-3 was non-self-transmissible under experimental conditions. Data mining suggested KpVP-3-type plasmids have emerged in different countries including China, Australia, and the USA. The emergence of this novel virulence plasmid might pose a potential threat to public health. Heightened efforts are required to study its dissemination mechanism.